Cell cycle transitions are potentiated by the degradation of positive and negative cell cycle regulators through the ubiquitin-mediated proteolytic pathway. Cul-2, a component of a ubiquitin-ligase complex, regulates diverse aspects of cell cycle progression. Human Cul2 functions with the VHL tumor suppressor protein in a CUL2/VCB complex. Germline mutations in VHL cause a hereditary cancer syndrome. In vertebrates, the CUL2/VCB complex contains four protein subunits, CUL2, Rbx1, Elongin C, and VHL, and has been shown to function as a ubiquitin ligase in vitro. In C. elegans, CUL-2 negatively regulates CKI-1 and is required for the G1-to-S phase transition in germ cells. Inactivation of maternal
cul-2 product results in an early embryonic arrest with only 24 cells on average. There are three major phenotypes in the
cul-2 mutant embryos: a defect in chromosome condensation, leading to the formation of multiple nuclei; a delay in mitotic progression, with six fold longer mitosis than in wild type; and a defect in cytoskeletal movements. Inactivation of a ubiquitin-ligase is expected to result in the accumulation of substrates. As CUL-2 is predicted to function as a ubiquitin ligase,
cul-2 mutants should have an accumulation of substrates that contribute to the observed phenotypes. We have performed a proteomic survey using two-dimensional gel electrophoresis to identify proteins whose levels change in
cul-2 RNAi animals relative to wild type. In addition to the expected increase in substrate proteins, the levels of certain other proteins may also increase or decrease as a secondary consequence of an increase in the level of transcriptional regulators. These secondary changes can also be observed in a proteomic screen and can give us information about the physiological role of
cul-2. We have optimized conditions for protein preparation and 2D-gel electrophoresis. We have found potential protein candidates that change in
cul-2 mutants relative to wild type. These proteins will be identified by mass spectrometry, and we hope to be able to present this data at the meeting.